Meeting News Coverage

JuniorSTAR half-unit pen to be marketed in Europe

A new half-unit insulin reusable pen that can be used with insulin glargine, insulin glulisine or recombinant human insulin has received the CE mark in the European Union, according to a manufacturer press release. The announcement was made at EASD 2013.

JuniorSTAR (Sanofi) delivers 1 to 30 units per injection in a lightweight, single-step dial back device. According to the press release, JuniorSTAR was surveyed by 167 patients and/or caregivers with type 1 diabetes (aged 6 to 18 years) in five European countries, yielding the following results:

  • 81% of patients/parents and 86% of nurses agreed it is easy to carry on a daily basis, due to its weight (approximately 34 g);
  • 98% of patients/parents and 94% of nurses agreed it is easy to read due to its large dose display and legible numbers;
  • 91% of patients/parents and 89% of nurses agreed dialing back was easy due to its single-step dial back, a feature that avoids insulin leakage; and
  • 93% of patients/parents and nurses surveyed agreed on its ease of use.

The European marketing of JuniorSTAR is expected next year, according to the press release.

For more information:

The 49th Annual Meeting of the European Association for the Study of Diabetes; September 24-27, 2013; Barcelona, Spain.

A new half-unit insulin reusable pen that can be used with insulin glargine, insulin glulisine or recombinant human insulin has received the CE mark in the European Union, according to a manufacturer press release. The announcement was made at EASD 2013.

JuniorSTAR (Sanofi) delivers 1 to 30 units per injection in a lightweight, single-step dial back device. According to the press release, JuniorSTAR was surveyed by 167 patients and/or caregivers with type 1 diabetes (aged 6 to 18 years) in five European countries, yielding the following results:

  • 81% of patients/parents and 86% of nurses agreed it is easy to carry on a daily basis, due to its weight (approximately 34 g);
  • 98% of patients/parents and 94% of nurses agreed it is easy to read due to its large dose display and legible numbers;
  • 91% of patients/parents and 89% of nurses agreed dialing back was easy due to its single-step dial back, a feature that avoids insulin leakage; and
  • 93% of patients/parents and nurses surveyed agreed on its ease of use.

The European marketing of JuniorSTAR is expected next year, according to the press release.

For more information:

The 49th Annual Meeting of the European Association for the Study of Diabetes; September 24-27, 2013; Barcelona, Spain.

    See more from European Association for the Study of Diabetes